Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vaxcyte (PCVX – Research Report), Cigna (CI – Research Report) and Alphatec Holdings (ATEC – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vaxcyte (PCVX)
In a report released yesterday, Seamus Fernandez from Guggenheim reiterated a Buy rating on Vaxcyte, with a price target of $116.00. The company’s shares closed last Friday at $53.57.
According to TipRanks.com, Fernandez is a 5-star analyst with an average return of
Currently, the analyst consensus on Vaxcyte is a Strong Buy with an average price target of $104.80, implying an 89.7% upside from current levels. In a report issued on January 23, Needham also maintained a Buy rating on the stock with a $110.00 price target.
See today’s best-performing stocks on TipRanks >>
Cigna (CI)
Guggenheim analyst Jason Cassorla maintained a Buy rating on Cigna today and set a price target of $318.00. The company’s shares closed last Friday at $274.11, close to its 52-week low of $262.03.
According to TipRanks.com, Cassorla has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cigna with a $332.08 average price target, a 22.3% upside from current levels. In a report issued on January 22, RBC Capital also maintained a Buy rating on the stock with a $344.00 price target.
Alphatec Holdings (ATEC)
Canaccord Genuity analyst Caitlin Roberts maintained a Buy rating on Alphatec Holdings today and set a price target of $25.00. The company’s shares closed last Friday at $14.83.
According to TipRanks.com, Roberts is a 3-star analyst with an average return of
Alphatec Holdings has an analyst consensus of Strong Buy, with a price target consensus of $24.33, implying a 62.2% upside from current levels. In a report issued on January 20, Lake Street also maintained a Buy rating on the stock with a $25.00 price target.
